TREATMENT PHARMA ApS: Financial statements 2024
CVR: 37208035
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
TREATMENT PHARMA ApS (CVR 37208035) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -36,904 and a net result of DKK -38,290 compared with DKK -47,171 the year before. Equity in the 2024 report amounted to DKK 85,536. The solvency ratio was 22.8%.
- Gross Profit
- DKK -36,904
- Profit/Loss
- DKK -38,290
- Equity
- DKK 85,536
- Total Assets
- DKK 375,547
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -37 t. | -38 t. | 86 t. | 0 |
| 2023 | - | -45 t. | -47 t. | -76 t. | 1 |
| 2022 | - | -23 t. | -24 t. | -29 t. | - |
| 2021 | - | -3 t. | -3 t. | -5 t. | - |
| 2020 | - | -3 t. | 163 t. | -3 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
TREATMENT PHARMA ApS has published its annual report for 2023. Gross profit came to DKK -44,723, and the net result was DKK -47,171.
As of January 16, 2024, Anne Simmenæs is registered as director of TREATMENT PHARMA ApS.
As of January 16, 2024, Tove Resen has stepped down as director of TREATMENT PHARMA ApS.
As of January 15, 2024, Power the Future ApS is registered as an owner of TREATMENT PHARMA ApS with an ownership share of 25%.
About TREATMENT PHARMA ApS
TREATMENT PHARMA ApS is a Danish company of the type Anpartsselskab based in Horsens, founded in 2015. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named TREATMENT ApS. The management consists of Anne Simmenæs. The company is owned by Tove Resen Holding ApS, Power the Future ApS and Anne Simmenæs Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 410,337 and a net result of DKK 101,980 compared with DKK -38,290 the year before. Equity in the 2025 report amounted to DKK 187,516.